Neuropsychological profile of Alzheimer's disease based on amyloid biomarker findings results from a South American cohort.

dc.creatorClarens, Maria Florencia
dc.creatorCrivelli, Lucia
dc.creatorCalandri, Ismael Luis
dc.creatorChrem Méndez, Patricio
dc.creatorMartin, María Eugenia
dc.creatorRusso, María Julieta
dc.creatorCampos, Jorge
dc.creatorSurace, Ezequiel
dc.creatorVázquez, Silvia
dc.creatorSevlever, Gustavo
dc.creatorAllegri, Ricardo Francisco
dc.date2021-01-27T17:23:44Z
dc.date2021-01-27T17:23:44Z
dc.date2020
dc.date.accessioned2023-10-03T19:42:55Z
dc.date.available2023-10-03T19:42:55Z
dc.identifierhttps://hdl.handle.net/11323/7778
dc.identifier10.1080/23279095.2020.1756816.
dc.identifierCorporación Universidad de la Costa
dc.identifierREDICUC - Repositorio CUC
dc.identifierhttps://repositorio.cuc.edu.co/
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/9171708
dc.descriptionObjective: Increased life expectancy and exponential growth of adults suffering from Alzheimer's disease (AD) worldwide, has led to biomarkers incorporation for diagnosis in early stages. Use of neuropsychological testing remains limited. This study aimed to identify which neuropsychological tests best indicated underlying AD pathophysiology.Methods: One hundred and forty-one patients with MCI (Mild Cognitive Impairment) were studied. A neuropsychological test battery based on the Uniform Data Set (UDS) from the Alzheimer's Disease Centers program of the National Institute on Aging (NIA) was performed and amyloid markers recorded; according to presence or absence of amyloid identified by positive PIB-PET findings, or low CSF Aβ42 levels, patients were separated into MCI amyloid-(n:58) and MCI amyloid + (n = 83) cases.Results: Statistical differences were found in all memory tests between groups. Delayed recall score at thirty minutes on the Rey Auditory Verbal Learning Test (AVLT) was the best predictor of amyloid pathology presence (AUC 0.68), followed by AVLT total learning (AUC 0.66) and AVLT Recognition (AUC 0.59) scores, providing useful cut off values in the clinical setting.Conclusions: Use of neuropsychological testing, specifically AVLT scores with cutoff values, contributed to the correct diagnosis of MCI due to AD in this SouthAmerican cohort
dc.formatapplication/pdf
dc.formatapplication/pdf
dc.languageeng
dc.publisherCorporación Universidad de la Costa
dc.relationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
dc.relationNeuropsychological Testing Predicts Cerebrospinal Fluid Amyloid-β in Mild Cognitive Impairment
dc.relationEarly neuropsychological detection of Alzheimer's disease
dc.relation“Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician
dc.relationMini-mental state-practical method for grading cognitive state of patients for clinicians
dc.relationUsefulness of Discriminability and Response Bias Indices for the Evaluation of Recognition Memory in Mild Cognitive Impairment and Alzheimer Disease
dc.relationThe validity of the Trail Making Test as an indicator of organic brain damage
dc.relationNeuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology
dc.relationCreation of the Argentina-Alzheimer Disease Neuroimaging Initiative
dc.relationThe learning profile of persistent mild cognitive impairment (MCI): A potential diagnostic marker of persistent amnestic MCI
dc.relationReduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects
dc.relationNeuropsychological Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease
dc.relationNeuropsychological Assessment, 4th Edn
dc.relationBoston Naming Test
dc.relationWechsler Memory Scale - Revised
dc.relationA Combination of Neuropsychological, Neuroimaging, and Cerebrospinal Fluid Markers Predicts Conversion from Mild Cognitive Impairment to Dementia
dc.relationThe Clinical Examination in Psychology/L'examen Clinique En Psychologie
dc.relationAlbert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CHThe diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines
dc.relationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
dc.relationThe Alzheimerʼs Disease Centersʼ Uniform Data Set (UDS): The Neuropsychologic Test Battery
dc.relationDifferential Memory Test Sensitivity for Diagnosing Amnestic Mild Cognitive Impairment and Predicting Conversion to Alzheimer's Disease
dc.relationSerial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
dc.relationEpisodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects
dc.relationCerebrospinal Fluid Biomarker Signature in Alzheimer's Disease Neuroimaging Initiative Subjects
dc.relationCombining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease
dc.relationCerebral Blood Flow in Dementia
dc.relationThe Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease
dc.relationDevelopment of a multilingual aphasia battery. Progress and problems
dc.relationA New Clinical Scale for the Staging of Dementia
dc.relationMemory function in very early Alzheimer's disease
dc.relationThe FAB: a Frontal Assessment Battery at bedside
dc.relationNeuropsychological Evaluation of Mild Cognitive Impairment: Three Case Reports
dc.relation??-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease
dc.relationNeuropathological and Neuropsychological Changes in “Normal” Aging: Evidence for Preclinical Alzheimer Disease in Cognitively Normal Individuals
dc.relationRe: De Jager, CA, et al. Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease
dc.relationNeuropsychological Prediction of Conversion to Alzheimer Disease in Patients With Mild Cognitive Impairment
dc.relationMemory Evaluation in Mild Cognitive Impairment using Recall and Recognition Tests
dc.relationProfiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease
dc.relationWAIS-III: Wechsler adult intelligence scale: Psychological Corporation
dc.relationA, for the Alzheimer's Disease Neuroimaging Initiative
dc.relationThe consortium to establish a registry for Alzheimer's disease (CERAD): I. Clinical and neuropsychological assessment of Alzheimer
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rightshttp://purl.org/coar/access_right/c_abf2
dc.sourceAppl Neuropsychol Adult
dc.sourcehttps://pubmed.ncbi.nlm.nih.gov/32349554/#affiliation-1
dc.subjectAb42
dc.subjectAlzheimer’s disease
dc.subjectcognitive biomarkers
dc.subjectdementia
dc.subjectmild cognitive impairment
dc.subjectneuropsychology
dc.titleNeuropsychological profile of Alzheimer's disease based on amyloid biomarker findings results from a South American cohort.
dc.typeArtículo de revista
dc.typehttp://purl.org/coar/resource_type/c_6501
dc.typeText
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typehttp://purl.org/redcol/resource_type/ART
dc.typeinfo:eu-repo/semantics/acceptedVersion
dc.typehttp://purl.org/coar/version/c_ab4af688f83e57aa


Este ítem pertenece a la siguiente institución